Moderna aims to make three billion doses of coronavirus vaccine

29 April 2021
moderna_therapeutics_large

Cambridge, USA-based mRNA specialist Moderna (Nasdaq: MRNA) is investing in manufacturing facilities to boost global supplies of its coronavirus vaccine in 2022.

Moderna now expects to supply up to three billion doses of the product next year, through its owned and partnered production sites, with the costs being met by the firm’s available funds.

The firm plans to double drug substance manufacturing at Lonza’s (SIX: LONN) Switzerland-based facility.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology